Evotec SE and Variant Bio partner to discover fibrosis treatments .

Evotec SE and Variant Bio partner to discover treatments for fibrosis-related diseases with no current cure. Using Variant Bio's genomic platform and Evotec's drug discovery expertise, they will identify small molecules targeting key fibrotic pathways, progressing towards clinical candidates. The risk-sharing partnership offsets Variant Bio's early drug development costs for a share of future upside.

April 18, 2024
4 Articles

Further Reading